Abstract:Strategies to address the problem of poorly water-soluble drugs encompass the conversion of a crystalline drug into an amorphous form to promote its apparent solubility and dissolution. Co-amorphous systems (CAMs) incorporate low molecular mass molecules (co-formers), which are mixed with the drug to form one single phase [1 Blaabjerg LI, Lindenberg E, Rades T, et al. Influence of preparation pathway on the glass forming ability. Int J Pharm. 2017;521(1–2):232–239.[Crossref], [PubMed] , [Google Scholar],2 Dengale SJ, Grohganz H, Rades T, et al. Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev. 2016;100:116–125.[Crossref], [PubMed], [Web of Science ®] , [Google Scholar]]. The aim of this study is to understand the capability of different co-formers (amino, carboxylic and sulphonic acids), in the production of CAMs with olanzapine by ball milling, solvent evaporation and quench cooling.Mixtures (2 g) of olanzapine (OLZ) and each co-former [l-aspartate (ASP); l-tryptophan (TRY); l-arginine (ARG); l-proline (PRO); citric acid (CIT); tartaric acid (TAR); oxalic acid (OXA); saccharine (SAC); potassium acessulfame (ACE); cyclamic acid (CYC)] in 1:1 molar ratios were submitted to ball milling (BM), solvent evaporation (SE) and quench cooling (QC). CAMs were evaluated for the OLZ solubility increase, co-formability and storage stability over time, by differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD) and Fourier-transform infra-red spectroscopy (FTIR).The BM technique presented the most promising results followed by QC and SE (Table 1), since more CAMs were produced. All the sulphonic acids (SAC, CYC and ACE) formed CAMs regardless of the technique used, presenting complete amorphization probably due to their higher ability to produce intermolecular interactions, like hydrogen-bonding, thus increasing the stability of CAMs (more than 8 weeks at 25 °C/11 and 53% RH). Conversely, amino acids were the least efficient in producing CAMs. Crystalline OLZ presented low solubility (40.1 mg/L) in water and a general increase in the solubility of the CAMs was observed. Carboxylic acids (TAR, CIT, OXA) achieved the biggest increase (up to 269 times, BM with TART) followed by sulphonic acids (up to 199 times, SE with SAC), unveiling the possibility of improved dissolution profiles and bioavailability. Discussion and conclusions: The study has shown the possibility of converting a crystalline drug into an amorphous entity, particularly when in presence of co-formers which stabilise the amorphous structures formed. In fact, with sulphonic acids, both SE and BM, achieved complete amorphization and successfully stabilised the CAMs obtained. Due to the noteworthy increase in solubility, resulting from co-amorphization, this technique is considered to be adequate to process active compounds with poor water solubility, such as OLZ.Table 1. Comparison of the of co-amorphization ability using different techniques and co-formers.

Powder Grinding Preparation of Co-Amorphous Β-Azelnidipine and Maleic Acid Combination: Molecular Interactions and Physicochemical Properties

Poly (amino acid)s as new co-formers in amorphous solid dispersion

Quantitation of DNP, digoxin, HCG and anti-DNP antibody by electronic data processing of latex antiglobulin reaction results.

Selection of Bionic Co-former Improves the Dissolution of Neohesperidin via Co-amorphous Solid Dispersion with Naringin

Design of Ternary Amorphous Solid Dispersions for Enhanced Dissolution of Drug Combinations

Optimization of a Twin screw melt granulation process for fixed dose combination immediate release Tablets: Differential amorphization of one drug and crystalline continuance in the other

Amino Acids As Co-Amorphous Excipients for Tackling the Poor Aqueous Solubility of Valsartan.

Co-amorphization of posaconazole using citric acid as an acidifier and a co-former for solubility improvement

Effect of Drug–Polymer Interaction in Amorphous Solid Dispersion on the Physical Stability and Dissolution of Drugs: The Case of Alpha-Mangostin

Co-crystalization of quercetin and malonic acid using solvent-drop grinding method

Crystallization Kinetics and Molecular Dynamics of Binary Coamorphous Systems of Nimesulide and Profen Analogs

Multicomponent Amorphous Solid Forms of Telmisartan: Insights into Mechanochemical Activation and Physicochemical Attributes

Co-formability, solubility enhancement and stability of olanzapine co-amorphous systems produced with different co-formers

Whiplash cultures.

Simultaneous Improvement of Dissolution Behavior and Oral Bioavailability of Antifungal Miconazole via Cocrystal and Salt Formation

Potential application of low molecular weight excipients for amorphization and dissolution enhancement of carvedilol

Co-Amorphization of Acemetacin with Basic Amino Acids as Co-Formers for Solubility Improvement and Gastric Ulcer Mitigation

Design and molecular insights of drug-active metabolite based co-amorphous formulation: A case study of toltrazuril-ponazuril co-amorphous

Design of an Achromatic Superconducting Magnet for a Proton Therapy Gantry

Co-Amorphous Solid Dispersion System for Improvement in Dissolution Profile of N-(((1r,4r)-4-((6-fluorobenzo[d]oxazol-2-yl)amino)cyclohexyl)methyl)-2-methylpropane-2-sulfonamide as a Neuropeptide Y5 Receptor Antagonist

Human papillomavirus vaccination: the United Kingdom s recommendation and update on European licensure and efficacy data.